ON THE APPLICATION OF KOMBOGLYZE PROLONG IN THE TREATMENT OF TYPE 2 DIABETES
ON THE APPLICATION OF KOMBOGLYZE PROLONG IN THE TREATMENT OF TYPE 2 DIABETES
Kasymova S.D., Akhmedova M.A., *Turdalieva N.M.
Course of endocrinology of State educational establishment «Institute of postgraduate education in health sphere of Republic of Tajikistan»
*Republic dinical œnter of endocrinology
Aim. Evaluate the effectiveness and safety of the application of komboglyze for the diabetics of type 2.
Materials and methods. 51 diabetics of type 2 took part in the clinical test of the komboglyze, which were divided into three groups depending on the type and dosage of the kombiglyze and metfogamm. Glycemia rate on an empty stomach of the patients, glycohemoglobin (НвА1С), body weight were assessed before and after 12-14 weeks of the beginning of the treatment.
Results. It is revealed that there is unsatisfied control of glycemia against background of previous dietetic therapy in the first group of the patients of type 2 diabetes, and assigning 1 tablet of komboglyze reliable improved the indicator of carbohydrate metabolism and glycohemoglobin.
In the second group of the patients with the decompensating of the disease in the light of 1000 mg of metfogamm previously received, the morning consumption was replaced by 1 tablet of komboglyze, and the evening dosage of metfogamm made up 500-1000 mg. 80% of the patients of this group had reliable decrease of fruit-sugar on an empty stomach, decreased body weight and target level of НвА1С reached.
In the third group with unsatisfied control of glycemia in the light of 1500-1700 mg of metfogamm, the increase of its dosage up to 2000-2500 mg per day led to unreliable decrease of fruit-sugar on an empty stomach, and the target value of НвА1С was not reached. The statistical processing of the results was conducted by using the reliability according to Student.
Conclusion. The effectiveness of the komboglyze as a drug for the patients with diabetes of type 2 with the unsatisfied initial level of disease compensation against dietetic therapy was revealed. The group which received combined therapy of komboglyze with metfogamo also had decrease in fruit-sugar level on an empty stomach and the target level of glycohemoglobin was reached.
REFERENCES
1. Mkrtumyan A. M., Podachina S. V., Sviridova M. A., Kanauzov M. Ya. Rezultaty i perspektivy primeneniya ingibitora DPP-4 [Results and perspectives pf the DPP-4 inhibitor]. Meditsinskiy sovet — Medical Council, 2013, no. 3, pp. 1-7.
2. Shestakova M. V. Opyt prmeneniya sitagliptina v lechenii sakharnogo diabeta 2 tipa v Rossiyskoy Federatsii: rezultaty nablyudatelnoy programmy «Dia-Da» [Experience of using of sitagliptin in the treatment of diabetes 2 type in Russian Federation: the results of observational program «Dia-Yes»]. Sakharnyy diabet — Diabetes mellitus, 2010, no. 3, pp. 57-60.
3. Goldstein B. J. et al. Effect of initial combination therapy with sitagliptin. A dipeptidil peptidase — 4 inhibitor and Metformin on Glycemic Control in Patients with type 2 diabetes. Diabetes care, 2007, vol. 30, pp. 1979-1987.
Комментарии